Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Percheron Therapeutics Limited (PER.AX)
Melbourne, VIC, AU
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.11% | +0.00% | +0.00% | -31.55% | -60.00% | -55.56% | -60.00% | -93.22% | -93.22% | -93.22% | -93.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+18.0% ★ Q4'25: +56.1% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q4'25: -473.0% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+53.1% Q4'25: +50.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
est: 1.20M (-100.0%)
|
—
est: 2.94M (-100.0%)
|
2.15M
2.15M – 2.15M
-26.8% YoY
|
1.97M
1.97M – 1.97M
-8.5% YoY
|
| EBITDA |
-11.84M
|
-16.27M
|
—
— – —
|
—
— – —
|
| EBIT |
-11.92M
|
-16.34M
|
—
— – —
|
—
— – —
|
| Net Income |
-11.92M
est: -14.63M (+18.5%)
|
-14.92M
est: -11.97M (-24.7%)
|
-7.98M
-7.98M – -7.98M
+33.3% YoY
|
-26.93M
-26.93M – -26.93M
-237.5% YoY
|
| SGA |
4.04M
|
5.87M
|
—
— – —
|
—
— – —
|
| EPS |
-0.02
est: -0.01 (-24.6%)
|
-0.01
est: -0.01 (-24.9%)
|
-0.01
-0.01 – -0.01
+33.3% YoY
|
-0.03
-0.03 – -0.03
-237.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-10 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-09 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-03 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-02 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Garner | Chief Executive Officer, MD & Director | 531.0K | — |
| Deborah Ambrosini | Company Secretary & Chief Financial Officer | 383.2K | female |
| Eugene Kennedy | Chief Medical Officer | — | — |
| Valentina Dubljevic GAICD | Chief Technology Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PER.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
